soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral soul trial oral semaglutide cardiovascular

Clinically, qualifying for GLP-1 therapy typically requires meeting one of two conditions: a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater combined with an obesity-related comorbidity such as type 2 diabetes or cardiovascular risk factors

Telehealth platforms including Heally allow you to consult with a licensed healthcare provider entirely online

Try to eat smaller and more frequent meals

Despite the overwhelming success of GLP-1 medications related to weight loss, GLP-1 therapy is associated with increased cerebral blood flow and reduced small-vessel disease burden, even when controlling for weight loss [15]

PMID 29767158

Compounded medications are prepared for an individual patient and are not FDA-approved